重组人血管内皮抑素联合长春瑞滨和顺铂治疗晚期非小细胞肺癌的疗效观察

目的探讨重组人血管内皮抑素联合长春瑞滨和顺铂对Ⅲb^Ⅳ期非小细胞肺癌(NSCLC)疗效。方法按照随机数字表法将58例ⅢbⅣ期非小细胞肺癌(NSCLC)疗效。方法按照随机数字表法将58例Ⅲb^Ⅳ期NSCLC患者分为对照组(28例)和观察组(30例)。对照组患者给予长春瑞滨和顺铂治疗,观察组患者在对照组的基础上联合使用重组人血管内皮抑素。比较两组患者近期治疗总有效率、临床受益率、生活质量改善率、血清癌胚抗原(CEA)的变化情况及不良反应发生率。结果观察组患者治疗总有效率、临床受益率及生活质量改善率分别为33.3%、73.3%和73.3%,高于对照组患者的14.3%、60.1%和35.7%(均P<0.05)。两组患者不良反应发生率比较,差异无统计学意义(P>0.05)。观察组患者治疗后平均血清CEA水平低于对照组(15.99±6.39)ng/ml和(32.60±5.61)ng/ml,P<0.05]。结论重组人血管内皮抑素联合长春瑞滨和顺铂可提高ⅢbⅣ期NSCLC患者分为对照组(28例)和观察组(30例)。对照组患者给予长春瑞滨和顺铂治疗,观察组患者在对照组的基础上联合使用重组人血管内皮抑素。比较两组患者近期治疗总有效率、临床受益率、生活质量改善率、血清癌胚抗原(CEA)的变化情况及不良反应发生率。结果观察组患者治疗总有效率、临床受益率及生活质量改善率分别为33.3%、73.3%和73.3%,高于对照组患者的14.3%、60.1%和35.7%(均P<0.05)。两组患者不良反应发生率比较,差异无统计学意义(P>0.05)。观察组患者治疗后平均血清CEA水平低于对照组(15.99±6.39)ng/ml和(32.60±5.61)ng/ml,P<0.05]。结论重组人血管内皮抑素联合长春瑞滨和顺铂可提高Ⅲb^Ⅳ期NSCLC患者治疗总有效率和临床受益率,改善患者生活质量,具有较好的协同作用和安全性,值得临床推广应用。

The clinical efficacy of recombinant human endostatin combined with vinorelbine and cisplatin for the treatment of roB.IV stage non-small cell lung cancer

Objective To investigate the recent clinical efficacy of recombinant human endostatin combined with vinorelbine and cisplatin for the treatment of Ⅲ B-Ⅳ stage non-small cell lung cancer （NSCLC）. Methods 58 cases of patients with Ⅲ B-Ⅳ stage NSCLC were divided into the control group （n = 28 ） and the observation group （n = 30） according to the random number table. The control group were received the treatment of vinorelbine and cisplatin, the observation group were given recombinant human endostatin on the basis of the control group. The recently total effective rate, clinical benefit rate, quality life improvement, serum carcinoembryonic antigen （CEA） and the changes in incidence of adverse reactions of the two groups were compared. Results The effective rate, clinical benefit rate and quality life improvement rates were 33.3%, 73.3% and 73.3%, which were all higher than those of the control group （ 14. 3% , 60. 1% and 35.7% ） （all P 〈0. 05）. The CEA level of the observation group were higher than that of the control group（ 15.99 ± 6. 39 vs 32. 60 ± 5.61 ） （ P 〈 0. 05 ）. Ana no significant difference of the incidence of adverse reactions of the two groups was found （P 〉 0. 05）. Conclusion Recombinant human endostatin combined with vinorelbine and cisplatin can improve patients＇ treatment efficiency, clinical benefit rate and quality of life for the treatment of Ⅲ B-Ⅳ non-small cell lung cancer, which has better synergy and security and is worthy of application.